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Background: Schizophrenic psychoses are severe mental disorders. Despite advances
in treatment, outcomes are still unsatisfactory. Pharmacological treatments are
still limited, in particular regarding improvements in psychosocial functioning and
neuro-cognitive impairment. In recent years new psychological therapies have been
developed, demonstrating promising results. However, most of these interventions
have been designed for and studied in outpatients; their efficacy and feasibility for
patients requiring hospitalization is still unknown. Therefore, we have designed a
clinical trial to compare a neuro-cognitive (Integrated Neuro-cognitive Treatment INT);
a cognitive-behavioral (Integrated Psychological Therapy IPT); and a control (Cogpack
CGP) intervention for patients with a schizophrenic psychosis hospitalized for treatment.
Methods: In a three-parallel-arm, single-blind, randomized, controlled study, we
compare INT, IPT, and CGP. Participants will take part in two weekly sessions of one
intervention for at least 16 sessions. If due to randomization, participants are allocated
to a treatment arm not suitable for them, they are allowed to switch intervention after
four sessions. Based on a sample size calculation, recruitment will continue until 30
participants have completed the intervention for each treatment arm.
Outcome Measurement: Primary outcomes are: change in symptom as measured by
the Positive and Negative Syndrome Scale (PANSS), change in psychosocial functioning
as assessed by the mini ICF-APP and neuro-cognitive performance, assessed by
the Matrics Cognitive Consensus Battery (MCCB). Other outcomes of interest are
the Brief Symptom Inventory (BSI) and the Health of the Nation Outcome Scales
(HoNOS); together with prescribedmedication, treatment retention and completion rates.
Outcomeswill bemeasured at baseline, 2 weeks into treatment (prior to a potential switch
of intervention arm), post-treatment and at 6 and 12-month post-treatment follow-ups.
Expected Outcomes: We expect an overall improvement; however, with differences
in specific domains for each treatment arm, with those completing INT showing
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Redlich Bossy et al. Psychological Interventions for Schizophrenia
better outcomes than IPT and CGP, respectively. We anticipate that lower functioning
participants will drift to CGP and higher functioning participants to INT.
Conclusion: Due to the complexity of treatment for patients with a schizophrenic
psychosis, we consider it crucial to compare different treatment options for those more
severely affected, therefore, requiring inpatient treatment.
Trial registration: www.clinicaltrials.gov (ID: NCT03316664; 17.10.2017).
Keywords: schizophrenic psychosis, randomized controlled trial, inpatient, CBT for groups, NCR, INT, IPT
BACKGROUND
Schizophrenic psychoses are severe mental disorders, with
a heterogeneous combination of symptoms and a lifetime
prevalence of around one per cent (1, 2). Characteristic
symptoms, albeit not exclusive, are hallucinations, delusions,
apathy, blunting of affect, disorganized speech and thinking,
together with cognitive impairment (3). Those affected are struck
in the prime of life and are frequently unable to cope with
the challenges of everyday life; experiencing impairment and
disability in multiple domains, including the ability to maintain
social relationships, sustain employment, and live independently
(1, 2).
The treatment of schizophrenic psychoses remains a
challenge; only around half of the patients show substantial
clinical improvement (4). Treatment of Schizophrenia still
relies predominantly on antipsychotic agents (5). Since their
clinical introduction over 60 years ago, the Dopamine D2
receptor antagonism remains the pivotal mechanism of
action. Newly developed antipsychotics follow the strategy of
maintaining this effect, while attempting to improve tolerability
(5). The pharmacological treatment of schizophrenia is
often limited due to side-effects (6–8). Overall, antipsychotic
agents are most effective in reducing positive symptoms, in
comparison other symptom domains, such as psychosocial
functioning, negative symptoms, and cognition show minimal
improvement (5, 9).
In the past few decades, psychological interventions
have been shown to be effective when used in conjunction
with pharmacological treatment (10, 11). Psychoeducation,
assertiveness training, family therapy, cognitive behavioral
therapy, and cognitive remediation treatment programs have
been developed and systematically studied and further improved
(10–15). Current guidelines recognize their importance for
treatment and outcome, correspondingly implementation
early on in treatment is recommended, even in hospitalized
patients (16–19). However, current evidence regarding the
effectiveness of psychotherapeutic interventions has been
obtained primarily in studies of outpatient populations; studies
in chronic and low functioning patients hospitalized for
treatment are sparse (20, 21), with patient recruitment a major
challenge (22).
The Integrated Psychological Therapy (IPT) for patients with
schizophrenia is one of the first manualized integrated cognitive
remediation therapy programs for groups, combining social
skills, neuro- and social cognition in a single therapy (23, 24).
Since the first trial in 1980, IPT has been extensively studied,
with empirical evidence consistently demonstrating its efficacy;
consequently, it is currently implemented in clinical practice
(25). The further development of IPT has led to Integrated
Neurocognitive Therapy (INT) for Schizophrenia, a manualized
cognitive remediation therapy, which includes a computerized
neurocognitive training component (Cogpack CGP) (26, 27). In
clinical trials INT has been shown to not only improve neuro-
social-cognitive performance but also to have the potential to
improve functional outcome and to reduce negative symptoms
(24, 27–29).
Although both INT and IPT seem to be effective treatments
for patients with schizophrenia; the therapeutic approaches
differ in terms of the symptoms they address, together with
how the intervention is delivered (29, 30). Through its plain
and straightforward design, IPT is suitable for chronic and
hospitalized patients (31). However, IPT does not target all the
cognitive domains impacted in schizophrenia (32). In contrast,
INT not only integrates these cognitive domains in its therapeutic
approach, it also includes elements designed to improve self-
awareness and perception of the environment. Furthermore, it
includes a computer-based cognitive training, with effects of its
own. Consequently, INT is a more complex and challenging
intervention than IPT for both therapists and participants (29).
Primarily for this reason, INT trials to date have been conducted
almost exclusively in outpatient settings (29, 30).
Generally, outpatients are less severely ill (33), which may
have implications regarding the implementation of INT for
patients requiring hospitalization for treatment. To the best of
our knowledge, there have been no trials directly comparing IPT
to INT; it is therefore not known if both therapy approaches
are equally effective or if one program works better for certain
patients or is indeed detrimental for others. Important factors
which need to be taken into account are the symptom load and
severity in patients requiring hospitalization for treatment, the
conditions of the treatment unit, in particular fluctuation in the
patient population, together with the presence of patients with
disturbing behavior (21).
Therefore, we plan to conduct a single-blind, randomized,
controlled trial comparing INT, IPT, and CGP in patients with
schizophrenia requiring hospitalization for treatment; to assess
the efficacy and feasibility of INT as a treatment programme for
such patients. The main outcomes for the assessment of efficacy
are changes in symptom load and functionality, together with
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TABLE 1 | Inclusion and Exclusion criteria.
Inclusion criteria
Participants are competent to give informed consent, as determined by the
referring physician or psychiatrist.
Diagnosis of Schizophrenia or Schizoaffective Disorder according to DSM-5 (34)
Participants are between 18 and 65 years of age.
Completion of regular compulsory education.
German language proficiency as a native speaker or level B1 Common European
Framework of Reference for Languages (CEFRL) (35)
Exclusion criteria
Unwilling or unable to comply with study instructions.
Low Intelligence as confirmed by failure to complete regular compulsory
education.
Currently in another psychotherapeutic treatment, either in individual or group
sessions.
Current consumption of alcohol or illicit drugs.
cognitive performance. Outcomes for feasibility are retention,
switch rates, and overall therapy attendance.
METHODS
Design
We have designed an 8-week, randomized, controlled, assessor-
blind, three-parallel-arm trial for patients diagnosed with
a schizophrenic psychosis. All patients with the diagnosis
of a schizophrenic psychosis (according to the DSM 5
Diagnostic criteria) are eligible to participate. In order to
allow the participation of chronic and low-functioning
patients, the inclusion criteria were deliberately broad
(see Table 1).
Recruitment
The Center for Integrative Psychiatry [ZIP: (German) Zentrum
für Integrative Psychiatrie], is part of the Psychiatric University
Hospital of Zurich specializes in treating “heavy-users,” i.e., those
patients with frequent or long-term hospitalizations for whom
outpatient treatment is often insufficient. Participants will be
recruited among the patients hospitalized for treatment in the
Unit for Psychotic Disorders of the ZIP.
Interventions and Therapists
Cogpack is a computer-based neuropsychological cognitive
training program, covering seven domains: visual-motor skills;
processing speed; vigilance; executive functions; memory; verbal
comprehension and problem- solving (26, 36). Tasks employed
will be identical to those used in the INT sessions. The difficulty
level of each task is adapted automatically by the program. At the
end of each task, the computer program generates a feedback-
report for every user on their performance including “percentage
correct” and “completion speed.” Cogpack will be delivered by a
psychiatric medical resident, with cognitive behavioral training
and a 2-h introduction to the computer program followed by
practical training.
Integrated Psychological Therapy (IPT) is a manualized
psychological intervention consisting of five modules (37). The
five modules are hierarchically arranged and deal with cognitive
deficits, perceptual deficits, verbal communication, social skills,
and problem-solving, with successively increasing complexity in
each module. The procedure and contents for each module are
broadly predefined and can be adapted to each group’s specific
needs. Therapists delivering IPT are nurses (as IPT has been
traditionally delivered) with basic training in cognitive behavioral
methods and a 3-day seminar on IPT followed by practical
training and regular supervision.
Integrated Neurocognitive Therapy (INT) is a manualized
psychological intervention consisting of four modules. Each
module consists of neuro- and social-cognitive elements,
together with stress and emotional regulation domains. The
complexity of the modules increases successively as do the
emotional demands. INT has a strategy-based-learning and a
drill-and-practice approach, where the same didactic structure
is applied to each domain (27, 38). One peculiarity feature
of INT is the integration of cognitive domains, together with
self-awareness/perception; and computer exercises (CGP) (26).
Therapists delivering INT have a psychology and psychotherapy
degree and have attended a 3-day seminar on INT, followed by
practical training and receive regular supervision.
Taking into account the usual length of stay in our unit,
together with current recommendations, we have adapted
both IPT and INT to 20 session programmes comprising the
contents of all modules, whilst respecting the specifications
and recommendations of the manuals. Cogpack modules are
analogous to those of INT. For an overview of the parallel
interventions according to TIDieR (see Table 2).
Randomization and Switch Procedure
Following baseline assessment, patients will be randomly
assigned (1:1:1 fashion) to either IPT or INT (active
interventions) or Cogpack (control intervention). We expect
six to eight participants in each treatment arm. Through
randomization, there is the possibility that some participants
will experience difficulties with their assigned treatment
group. In such cases, patients will be permitted to switch to
another treatment arm after 2 weeks. The sole criterion for
switching intervention arm is patient preference due to excessive,
respectively insufficient demands. We have chosen not to
formulate explicit criteria for switching intervention arm for two
reasons; first of all to empower patients in their commitment to
therapy; second to prevent bias through the delayed selection
of participants.
After participation in a minimum of 16 sessions (60–90min
each) in one treatment arm, the intervention will be completed;
follow-up assessments will be carried out at 6 and 12 months. For
a Study- Flow diagram (see Table 3 and Figure 1).
Ethical and Regulatory Considerations
The study will be conducted in Switzerland in accordance
with current regulations. The ethics committee of the Canton
of Zurich approved the study protocol (BASEC Nr.: 2017-
01351). The study protocol was registered in clinicalTrials.gov
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TABLE 2 | Content and chedule of Interventions (ToM: Theory of Mind).
IPT INT CGP
First Block Module 1 Module A Module A
Sesion 1 Card sorting Information processing Information processing
Sesion 2 Verbal concept Attention/vigilance Attention
Sesion 3 Verbal concept Perception of emotions Attention
Sesion 4 Search strategies Perception of emotions Vigilance
Second Block Module 2 Module B Module
Sesion 1 Information collection Verbal and visual learning Verbal and visual learning
Sesion 2 Interpretation and discussion Memory Memory
Sesion 3 Interpretation and discussion Social perception (ToM) Memory
Sesion 4 Title finding Social perception (ToM) Verbal and visual learning
Third Block Module 3 Module C Module C
Sesion 1 Repetition/paraphrasing Thinking / problem solving Thinking / problem solving
Sesion 2 Questions and answers Problem-solving Thinking / problem solving
Sesion 3 Asking questions Problem-solving Thinking / problem solving
Sesion 4 Focussed communication Problem-solving Thinking / problem solving
Fourth Block Module 4 Module C / Module D Module C /Module D
Sesion 1 Cognitive processing Social schemata Thinking / problem solving
Sesion 2 Cognitive Processing Social schemata Thinking / problem solving
Sesion 3 Role-playing games Working memory Working memory
Sesion 4 Role-playing games Working memory Working memory
Fifth Block Module 5 Module D Module D
Sesion 1 Problem identification Attribution Working memory
Sesion 2 Generating solutions Attribution Working memory
Sesion 3 Generating solutions Attribution Working memory
Sesion 4 Implementing solutions Emotion regulation Working memory
(NCT03316664; 17.10.2017). Written informed consent will be
obtained from the participants before study enrollment.
Assessments of Outcomes, Raters
Study measurement and outcomes will be assessed by raters
blinded regarding group allocation and treatment of the
participants. Raters have a psychology degree and training in
research methods. All raters have been systematically trained
in the use of the study instruments. To ensure raters are blind
to treatment arm, they will have no access to patient or study
records beyond the strict requirements for rating.
Furthermore, rating sessions will be conducted outside the
ward and treatment facilities. In the case of a participant revealing
treatment arm allocation to the rater this will be documented.
Following the completion of the study, such violations of blinding
will be analyzed to determine whether they modified the results.
Assessment of Outcome, Instruments
Primary outcomes are change in symptom load as measured
by the Positive and Negative Syndrome Scale (PANSS) (39),
in level of functioning as assessed by the MINI ICF- APP
(40) and performance in the Matrics Cognitive Consensus
Battery (MCCB) (32). Other outcomes of interest are symptoms
and complaints as measured by the Brief Symptom Inventory
(BSI) (41), overall severity (or improvement) as measured
by the Clinical Global Impression (CGI) (42) scales, overall
functionality as measured by the Global Assessment of
Functioning (GAF) (43), along with overall mental health
as measured by the Health of the Nation Outcome Scales
(HoNOS) (44). An overview of the outcome measurements
is given in Table 4. Besides these measurement instruments,
basic demographic, and clinical characteristics together with
medication will also be collected.
Statistical Analysis
We calculated our required sample size using G∗Power 3.1 (51)
(ANOVA: Repeated measures, three groups, four measurement
points; effect size F = 0.25; < = 0.05; Power = 0.80; number of
groups = 3). Based on that calculation, at least 90 participants
(30 in each study arm) completing the intervention are required
in order to detect small to moderate size differences. Cohen’s d
(effect size) will be used to compare the percentage of variation in
the groups before and after treatment.
All data sets of participants will be analyzed, on an intention
to treat basis. Data at baseline, second week and after the
intervention, as well as at 6 and 12-months post-intervention
will be considered (see Table 3). The demographic and clinical
characteristics of the sample will be compared at baseline
using an analysis of variance (ANOVA), except for gender and
age, which will be assessed using an analysis of covariance
(ANCOVA). To compare the overall effect of treatment over time
in the three groups, data from the full intent to treat sample
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TABLE 3 | Schedule of enrolment, interventions, and assessments.
Study period
Enrolment Allocation Post allocation Close-out
Time Point –t1 t0 t1 t2 t3 t4 t5
Enrolment
Eligibility screen X
Informed consent X
Allocation X
Switch X
Interventions
INT
IPT
Cogpack
Assessments
Demographic data X X
Psychopathology X X X X X
Psychosocial functionality X X X X X
Neurocognition X X X X X
Medication X X X X X
Safety X X
FIGURE 1 | Study flow chart.
will be analyzed using a repeated-measures analysis of variance
(ANOVA) with treatment as the intergroup factor and time as
the intrasubject factor. Post-hoc analyses will be performed using
Student’s t-test for intergroup comparisons. Reported adverse
effects and safety-related events will be analyzed separately as will
withdrawal from the study or treatment group changes.
Participants Switching Groups, Drop-Outs,
and Missing Data
Drop-outs will be replaced until the calculated number
of participants has completed the intervention; all enrolled
participants will be allowed to complete the intervention. Patient
switching therapeutic arm will be considered as drop-outs and
will be replaced correspondingly; however, they will be allowed
to complete the intervention and outcomes will be assessed as
scheduled. For all dropouts, an additional intention to treat, and
last observation carried forward analysis will be performed.
In contrast to drop-outs the assessment of outcomes and
observation of participants switching groups will be continued.
Data prior to switching will be analyzed and reported
separately in order to avoid bias duplication of results for a
particular participant.
The outcomes of those participants who completed the
intervention after switching groups will undergo a post-
hoc analysis with those who completed their treatment
intervention without switching. A multivariate analysis of
variance (MANOVA) will be performed, taking into account the
switch of intervention together with outcomesmeasured pre- and
post-intervention; i.e., ignoring the outcomes at week two for
those not switching intervention arm. Groups for analysis will
be constructed according to the number of participants actually
switching interventions: the effect of the four first sessions
will be categorized according to the change and included in
the analysis.
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TABLE 4 | Outcome measurements.
Test instrument Description
Positive and Negative
Syndrome Scale
(PANSS)
The PANSS is a semi-structured interview designed to
measure the severity of psychopathology in adult
patients with a psychotic disorder, mainly schizophrenia
and schizoaffective disorder (39, 45). It measures
symptoms in three domains, positive (seven Items),
negative (seven items), and general-non-specific
symptoms (16 items). Each item is rated on a
seven-point Likert scale: from 1 (not present), and from 2
(present) to 7 (very severe). The PANSS range is from 30
to 210 (39).
Mini ICF—APP The Mini-ICF-APP was developed (40), as a short
observer-rated scale for assessing the level of
functioning according to the International Classification
of Functioning, Disability, and Health (ICF). It assesses 13
domains of functioning, with anchor definitions provided
in the manual. Each item is rated on a five-point Likert
scale from 0 (no disability) to 4 (total disability).
MATRICS Consensus
Cognitive Battery
(MCCB)
The MATRICS (Measurement and Treatment Research to
Improve Cognition in Schizophrenia) Consensus
Cognitive Battery was developed to provide a relatively
brief evaluation of key cognitive domains relevant to
schizophrenia and related disorders (46). The test
Battery includes 10 tests which represent seven different
cognitive domains; the test battery is administered as a
unit in a standard order. To facilitate a valid interpretation
of test scores psychometric properties and normative
data were also analyzed (47).
Clinical Global
Impression (CGI)
The CGI scale is a brief, easy to use and pragmatic tool
for the assessment of psychiatric illness severity and
changes over time (42, 48, 49). The CGI consists of
three subscales: 1. Severity of Illness (CGI-S), 2. Global
Improvement (CGI-I), and 3. Efficacy Index (CGI-E).
CGI-S and CGI-I have a seven-point Likert scale
response format. It ranges from 1 representing the
“healthy subject” to 7 the “extremely ill subject.” The
CGI-I ranges from 1 “significant improvement” to 7 “most
severe deterioration,” whereby a score of 4 indicates no
change. The CGI-E relies on several parameters from
whom an index is calculated.
Global Assessment of
Functioning (GAF)
The GAF is an observer-rated, 100-point single item
scale that rates overall functioning on a continuum from
mental health to mental illness (43). The scale ranges
from 1 (representing the most impaired individual) to 100
(representing the healthiest individual), divided into (10)
deciles, 0 denoting insufficient information to make a
judgment.
Health of the Nation
Outcome Scales
(HoNOS)
The HoNOS is an observer-rated scale and consists of
12 items with a five-point Likert scale response format
from 0 (no problems) to 4 (severe/very severe problems).
Scores above two are considered clinically significant.
The items were combined into four dimensions; each
subject can be evaluated on items, subscale scores and
the total score (44, 50).
If a participant withdraws from the study, his data will be
anonymized, and his name will be deleted permanently from
the study.
Data Sharing and Publication
After completion of the study, a report for publication in a
peer-reviewed journal will be prepared. The manuscript will
TABLE 5 | Expected outcomes.
Intervention
Expected outcomes INT IPT Cogpack
Overall improvement (CGI) + + +
Overall functionality (GAF) +++ ++ +
Prescribed medication + ++ +++
Drop out-switch of treatment group +++ ++ +
Completion of therapy ++ ++ +++
Symptom load (PANSS) + + +
Symptom perception (BSI) ++ ++ +
Psychosocial functioning (mini ICF) ++ ++ +
Psychosocial functioning (HoNOS) ++ ++ +
Neurocognitive performance (MCCB) +++ + ++
Speed of processing ++ + +++
Verbal learning +++ ++ +
Working memory (non- verbal) ++ + ++
Working memory (verbal) ++ ++ +
Reasoning and problem solving +++ ++ ++
Visual learning ++ + +++
Social cognition ++ ++ +
Attention/Vigilance +++ ++ +++
be edited/compiled according to the CONSORT statement
recommendation (52–54). The study protocol has been registered
at: www.clinicaltrials.gov (ID: NCT0331664; 17.10.2017). The
study protocol was written according to the SPIRIT 2013,
statement for reporting of trial protocols (55) and the TIDieR
guidelines (56).
Expected Outcomes
We expect all treatment arms to show similar overall rates of
improvement; with differences in specific domains. Regarding
symptom load, we do not expect any treatment arm to perform
significantly better than the others. Regarding psychosocial
functioning, we expect INT and IPT to be superior to
CGP. Regarding cognitive abilities, we expect that patients
participating in INT will perform better than both CGP and
IPT participants.
Regarding the feasibility and implementation of the treatment
arms, we expect similar retention rates in all treatment arms.
Moreover, we anticipate that chronic and lower functioning
participants will switch to CGP; whereas higher functioning
participants may switch to INT, with lower fluctuation in IPT.
Consequently, we anticipate slightly higher retention rates for
IPT, followed by INT and CGP. For an overview of the expected
outcomes (see Table 5).
DISCUSSION
Schizophrenia is a severe chronic disorder; those affected are
frequently not able to cope with everyday challenges. Despite
advances in treatment and an increase in treatment options
the proportion of patients with schizophrenia who fully recover
remains practically unchanged, this holds especially true for
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those requiring hospitalization for treatment (4, 57), however, for
methodological reasons, those severely affected by a psychiatric
disorder (i.e., those requiring hospitalization) are frequently
excluded from studies testing new treatment interventions
(58, 59).
The implementation of a new treatment intervention in
clinical practice and moreover in an inpatient setting is a
major challenge presenting a number of methodological and
logistic problems. Firstly, patients hospitalized for treatment
are generally more heterogeneous, with several co-morbid
conditions, as well as being more severely affected than
those typically included in studies. Especially patients with
psychotic disorders who are more severely affected tend to
have less insight and treatment motivation; consequently, they
are less likely to enroll in therapy. Furthermore, the very
negative and cognitive symptoms which require treatment may
themselves interfere with treatment. Participants may, therefore,
be unable to cope with the demands of therapy, leading to
demotivation and frustration, which may lead to drop-out from
therapy. We have therefore chosen to compare three treatment
interventions with similar therapeutic targets and approaches,
but differing participation (for patients) and implementation (for
therapists) thresholds.
In clinical practice, factors relating to a patient which may
affect the therapeutic outcome are considered before initiating
treatment. This procedure is, however, incompatible with a
randomized assignment of treatment. Furthermore, it makes
it impossible to determine if a treatment is really feasible
for a group of participants. Therefore, we chose to allow a
switch of treatment groups after four sessions, a challenging
methodological alternative which should, however, facilitate
participants finding the appropriate therapy whilst allowing us
to achieve our study goals. The decision to switch from one
intervention to another is entirely the participant’s choice. This
approach strengthens the commitment of participants toward the
therapy (60), by reducing feelings of failure or inadequacy which
may be raised by psychometric and neurocognitive testing (61).
Furthermore, we consider this approach will reduce a potential
delayed selection bias.
Taking into account that participants switching treatment
arms will continue their treatment, we have decided to continue
the assessment of outcomes. Baseline severity will, in such cases,
correspond to the time when the main therapy began. This has
as a consequence that in addition to the three original treatment
arms other treatment arms emerge, namely those of switching
from one treatment to another. Since we are not able to accurately
foresee how many participants will use this option, and if so
to which treatment option they will switch, we have decided to
include this in a post-hoc analysis. To avoid bias and duplication,
we will consider participants switching groups as drop-outs in the
primary analysis.
The assessment of outcomes uses a variety of instruments
measuring symptom load, neuro-cognitive performance and
psychosocial functionality since we expect each treatment arm
to show a unique response profile (11). For symptom load, we
have chosen to use the PANSS, since it is considered the most
specific and validated scale for measuring change in patients
with a schizophrenic psychosis (62, 63). The MCCB is regarded
as the standard test battery for use with patients diagnosed
with schizophrenia; it is claimed as both robust to learning
effects and sensitive to change (47). Taking into account that
improvements in symptomatology and neuro-cognition should
lead to increased autonomy, we have chosen the mini-ICF-APP
to assess psychosocial-functioning independently of the main
diagnosis (40, 64, 65). Using this set of outcome measures, we
expect to assess all facets of the interventions, whilst facilitating
the interpretation and comparison of our results with those from
previous studies (63).
We anticipate an overall improvement in all participants,
regardless of group allocation. This may be attributable to
pharmacological treatments administered to the participants. For
the same reason, we do not anticipate significant differences in
symptom load. However, we do not exclude to find differences
in dose equivalents of administered medication, primarily
antipsychotics and benzodiazepines. Furthermore, we hope for
a reduction of polypharmacy. In order to quantify this effect;
medication, respectively dose and dose equivalents, will be taken
into account as possible confounders (66). Pharmacological
treatment will not be restricted since we consider withholding
or delaying pharmacological treatment for methodological or
design purposes to be unacceptable; furthermore, in clinical
practice, psychological interventions are used as an add-
on to pharmacological therapy (11). Offering just a single
psychotherapeutic treatment could be ineffective for some
patients and at worst detrimental, which could lead to treatment
abandonment (67). An intervention which is neither accepted
nor tolerated by participants should not be imposed on them.
The allocation of a patient to a treatment arm which does
not meet his needs is considered to be unacceptable and
may have detrimental effects. To avoid this situation, we have
decided to allow participants to switch groups under particular
conditions. We consider this approach to be both appropriate
and compatible with the trial objectives since we are also
interested in evaluating feasibility. In order to minimize the effect
of group changes on the primary and secondary outcomes of
the study, and to have similar treatment duration and number
of sessions, we have chosen to conduct a second assessment
prior to a (potential) change of groups. We consider 2 weeks,
respectively four sessions, sufficient to determine the suitability
and safety of a therapy. INT in outpatient setting shows low drop-
out rates and high rates of attendance which indicates a high level
of acceptance and motivation and lends support feasibility (29).
Another aim of this study is to evaluate whether this also applies
to inpatient settings.
Another challenge of this trial was the adaptation of a
treatment (INT) designed for outpatients to an inpatient setting
(29, 38). The hierarchical structure of the intervention, the
density of the therapeutic sessions, and the duration of the
therapy had to be taken into account together with the fact
that the original therapeutic design foresees closed therapeutic
groups (27). For its implementation in an inpatient setting, we
subdivided the intervention into modules or blocks comprising
of four sessions, allowing the participants to join the therapy
at specified times thus allowing for (semi)closed groups. The
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disadvantage of this approach lies in the hierarchical structure of
both INT and IPT interventions (23, 27), which leads participants
potentially starting with a more challenging topic; to minimize
this effect blocks or modules also had a bottom-up structure
allowing new participants to integrate quickly into the group.
Lower functioning patients with low functioning, including
those with chronic schizophrenia, seem to benefit from higher
frequency psychotherapy (21, 68). We, therefore, concluded that
two weekly sessions of 90min would fulfill this demand. Taking
into account the usual length of stay in our unit (6 to 8 weeks),
together with current guidelines (17–19) we have chosen to offer
at least 16 sessions to participants. For methodological reasons it
was not possible to condense both therapeutic interventions to
this number of sessions, therefore IPT, INT and CGP have been
adapted to 20 sessions programs, respecting the specifications of
the treatment manuals.
We considered this to be compatible with the average length
of stay in our unit, since some patients remain in treatment for
more than 8 weeks. Participants are also encouraged to continue
participation after discharge. Although we consider that the
completion of a treatment programme to be an important factor
determining response, evidence suggests that response is not
associated with treatment duration and number of sessions (10).
There is reason to believe that the three treatment arms
will differ from one another due to top-down and integration
effects on multiple domains. In respect of social- and neuro-
cognition, we expect INT and IPT to outperform CGP (36, 69).
Nevertheless, we cannot rule out that CGP may also lead to
improvements in neuro-cognitive abilities, in particular MCCB
domains tested on the computer due to learning and practice
effects (12, 70). We expect INT participants to achieve a higher
psychosocial performance than CGP, but similar to those of IPT.
Although INT and IPT have common roots, applying similar
technics for social cognition (23, 27, 37), we expect INT to deliver
better outcomes due to its higher complexity and integrative
approach (see Table 5).
In our study, we wish to evaluate the feasibility of a
psychotherapeutic intervention in a unit specialized for the
treatment of chronic and low functioning patients with a
schizophrenic psychosis. Therefore, the effort required to
implement such regular group psychotherapy will also be taken
into account. The IPT treatment programme is manualized
and has traditionally been delivered by nursing staff after an
introductory seminar and workshop (23). The implementation
of INT is more challenging since it also requires a trained
psychotherapist (27). CGP, on the other hand, is easily
implemented and requires practically no training to deliver (26,
71, 72). However, professional experience is a significant factor
predicting therapy outcome. Moreover, the therapist variable is
an essential factor relating to motivation to participate in the
therapy and influencing drop-out rates (73–75). Consequently,
all therapists running groups in this study will receive regular
supervision and training.
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